Overcoming Intrinsic and Acquired Temozolomide Resistance in Glioblastoma: Fisetin as a Potential Strategy to Enhance
Sena Ferah1, Mine Çamlıbel1, Melis Erçelik1
1Bursa Uludağ University Faculty of Medicine, Department of Medical Biology, Bursa, Türkiye.
Objectives:
Glioblastoma (GB) is the most aggressive type of brain tumor in adults, and the chemical agent temozolomide (TMZ) is widely used for its treatment. However, TMZ resistance can lead to therapeutic failure. The aim of this study was to investigate the effect of the bioflavonoid fisetin on GB cell growth and on overcoming TMZ resistance in TMZ-sensitive, inherited-resistant, and acquired-resistant GB cells the effect of fisetin on TMZ efficacy evaluin primary GB cells.
Materials And Methods:
GB cell lines (T98G; intrinsic TMZ-resistant, A172; TMZ-sensitive, A172-R; acquired TMZ-resistant) and primary GB cells derived from patient samples were treated with effective doses of TMZ (ranging from 900 to 1000 μM), fisetin (ranging from 13.78 to 16.40 μM), or a combination of both. TMZ resistance was acquired in A172 cells through stepwise increases in TMZ concentration. Real-time cell proliferation was measured using the xCELLigence system. The migratory capacity of the cells was evaluated using a wound-healing assay. The RNA expression of the epithelial-to-mesenchymal transition (EMT)-inducing transcription factor E-box-binding homeobox 1 (ZEB1) was assessed by quantitative polymerase chain reaction. Cell assays were analyzed by analysis of variance, and ZEB1 expression was analyzed by t-test.
Results:
Fisetin substantially enhanced the effect of TMZ in all the cell lines included in the present study, as evidenced by significant decreases in cell proliferation and wound-healing, and in ZEB1 expression (p<0.0001). In addition, TMZ+fisetin reduced ZEB1 expression in primary GB tumors but not in butterfly GB cells.
Conclusion:
Fisetin alone was effective against GB; importantly, the TMZ+fisetin combination demonstrated greater efficacy than TMZ alone by enhancing sensitivity to TMZ through downregulation of ZEB1 in various resistant models, including patient-derived samples. Since ZEB1 is associated with EMT and drug resistance, fisetin may be a promising anticancer candidate to improve chemotherapeutic efficacy in resistant GB and to shed light on personalized treatments, pending further preclinical research.
Insights
The bioflavonoid fisetin enhances temozolomide (TMZ) efficacy against glioblastoma (GB) by reducing cell proliferation and overcoming TMZ resistance. This combination therapy shows promise for improving glioblastoma treatment outcomes.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Glioblastoma (GB) is an aggressive brain tumor with limited treatment options.
- Temozolomide (TMZ) is a standard chemotherapeutic agent for GB, but resistance often leads to treatment failure.
- Investigating novel therapeutic strategies to overcome TMZ resistance is crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the effect of the bioflavonoid fisetin on glioblastoma (GB) cell growth.
- To determine if fisetin can overcome temozolomide (TMZ) resistance in various GB models.
- To assess the impact of fisetin on TMZ efficacy in primary GB cells and its mechanism involving ZEB1.
Main Methods:
- Utilized established and acquired temozolomide (TMZ)-resistant glioblastoma (GB) cell lines, alongside primary GB cells.
- Treated cells with TMZ, fisetin, or a combination, measuring proliferation via xCELLigence and migration via wound-healing assays.
- Assessed RNA expression of the epithelial-to-mesenchymal transition (EMT) marker ZEB1 using quantitative PCR.
Main Results:
- Fisetin significantly enhanced the anti-cancer effects of TMZ, reducing cell proliferation and migration in all tested GB cell lines.
- The combination of TMZ and fisetin led to a significant downregulation of ZEB1 expression in primary GB tumors.
- Fisetin demonstrated efficacy against GB and improved TMZ sensitivity by downregulating ZEB1 in resistant models.
Conclusions:
- Fisetin potentiates TMZ efficacy in glioblastoma (GB) by enhancing sensitivity and downregulating ZEB1, a key factor in EMT and drug resistance.
- The combination of TMZ and fisetin represents a promising strategy for overcoming therapeutic resistance in GB.
- Fisetin holds potential as an anticancer agent for improving chemotherapeutic efficacy in resistant GB, supporting personalized treatment approaches.
Related Concept Videos
01:22Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
02:18Intrinsically Disordered Proteins
02:18Intrinsically Disordered Proteins
03:00Self-Evaluation: Self-Enhancement and Self-Verification
03:02Standard Electrode Potentials
01:20Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...